Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
Open Access
- 25 October 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 47 (3) , 428-435
- https://doi.org/10.1016/j.ejca.2010.09.030
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline (HT/br/06 037)
- Dutch National Institute for Public Health and the Environment (3022/07 DG MS/CvB/NvN)
This publication has 24 references indexed in Scilit:
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- Modeling Cervical Cancer Prevention in Developed CountriesVaccine, 2008
- Cost-effectiveness of Human Papillomavirus Vaccination in the United StatesEmerging Infectious Diseases, 2008
- Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsThe Lancet, 2007
- Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmesVaccine, 2006
- Chapter 2: The burden of HPV-related cancersVaccine, 2006
- Evaluating Human Papillomavirus Vaccination ProgramsEmerging Infectious Diseases, 2004
- Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 VaccineJNCI Journal of the National Cancer Institute, 2004
- Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening ProgramsJAMA, 2003
- Cost Effectiveness of a Potential Vaccine forHuman papillomavirusEmerging Infectious Diseases, 2003